Kirk Tanner

Company: National Brain Tumor Society
Job title: Chief Scientific Officer
Seminars:
DDRi R&D in CNS Tumors: Landscape & Opportunities 3:30 pm
Understanding the strong rationale for DDRi’s in CNS Tumors Optimizing systematic and efficient experimental drug qualification as a key opportunity to make profound impact on devastating diseases with a strong commercial caseRead more
day: Day Two
Panel Discussion: PARPi’s: The Whole Story? PARP & DDR Biomarkers, Targets & Hope in Indications Outside of Breast & Ovarian 9:30 am
Sharing insights into future directions and what to anticipate as standards evolve for PARP and other DDRi’s in the clinic How is it looking for prostate? leukemia? GBM? pancreatic? endometrial? SCLC? What are the differences between cancers in terms of resistance to PARP inhibitors? Thoughts on moving to a more genomic rather than indication-specific biomarker-driven…Read more
day: Day One